Double layer spherical nanoparticles with hyaluronic acid coating to enhance oral delivery of exenatide in T2DM rats
GLP-1 therapy is non-invasive isnt that enough for many patients? For some patients, GLP-1 therapy may be appropriate, especially early or in mild obesity
Supporting Data: Novo Nordisk cuts Ozempic/Wegovy to $675 monthly starting Jan 1, 2027
The evidence indicates that dulaglutide may modulate central neurocognitive pathways through both direct brain access and peripheral-to-central signaling mechanisms [70]
Loyo and colleagues recently reviewed the United States Veterans Health Administration database, and identified 121,174 patients with T2DM and ischemic heart disease, cerebrovascular disease, or peripheral arterial disease who had been prescribed SGLT2is, GLP-1RAs, or their combination